About This Project
Summary
EBRP's Venture Philanthropy model leverages concepts from principal investing and applies them towards achieving philanthropic goals to find a cure for Epidermolysis Bullosa (EB). We go out, find the most promising research projects, and fund them in exchange for a financial interest in the work of university or business. When those projects have commercial success, we take the returns from our shares and plow them right back into more promising EB research projects until a cure is found.
Goals & Objectives
EB is a life-threatening rare skin disease that primarily affects children. EB is a perfect case study for our Venture model because as a rare, often unknown disease, it can be difficult to find funding. But now, we've created a sustainable philanthropic cycle that is also accelerating treatments.
Results & Impact
120+ Venture Philanthropy deals, 25x more EB clinical trials, 3 EB treatments: We made a 110% return on an investment which ultimately became Vyjuvek, the 1st FDA-approved EB treatment, and realized a 600% return on investment which recently became Zevaskyn, the first cell-based gene therapy for EB.
JOIN THE NEWSLETTER